(Q24202081)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

meta-analysis

0 references

title

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

Albina F Titarenko

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

6 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

CD004795

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Activity of amoxicillin/clavulanate in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Hepatotoxicity of pyrazinamide: cohort and case-control analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Levofloxacin treatment of active tuberculosis and the risk of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Fluoroquinolones for the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Safety and efficacy of a quinolone-based regimen for treatment of tuberculosis in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

The clinical use of fluoroquinolones for the treatment of mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Fluoroquinolones, tuberculosis, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

The global tuberculosis situation and the new control strategy of the World Health Organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Treatment of latent tuberculosis infection in HIV infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Clinically significant interactions with drugs used in the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Fluoroquinolones for treating tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Fluoroquinolones for treating tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Activity of quinolones against mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB4

Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes f

21 January 2018

1 reference

12 December 2020

[Bronchofiberscope and catheter intervention in treatment of multi-drug resistant pulmonary tuberculosis]

1 reference

12 December 2020

[Antituberculosis effect of levofloxacin]

1 reference

12 December 2020

Contacts of cases of active pulmonary tuberculosis

1 reference

12 December 2020

A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Evaluation of new antitubercular agents--new quinolone agents

1 reference

12 December 2020

A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis

1 reference

12 December 2020

Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis

1 reference

12 December 2020

Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs.

1 reference

12 December 2020

Treatment of urogenital tuberculosis with ofloxacin. Preliminary study

1 reference

12 December 2020

Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.

1 reference

12 December 2020

Adrenocortical function in hospitalised patients with active pulmonary tuberculosis receiving a rifampicin-based regimen -- a pilot study.

1 reference

12 December 2020

Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

1 reference

12 December 2020

[Efficiency of a new standard chemotherapy regimen in the treatment of patients with recurrent pulmonary tuberculosis]

1 reference

12 December 2020

[A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis]

1 reference

12 December 2020

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

1 reference

12 December 2020

Use of molecular-biological microchip TB-BIOCHIP-2 for detecting of Mycobacterium tuberculosis with multidrug resistance to fluoroquinolones in patients with new detected and chronic tuberculosis

1 reference

12 December 2020

A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.

1 reference

12 December 2020

Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study

1 reference

12 December 2020

Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.

1 reference

12 December 2020

[Roncoleukin in enhancing the efficiency of complex therapy for infiltrative pulmonary tuberculosis in adolescents]

1 reference

12 December 2020

[Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis]

1 reference

12 December 2020

Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial

1 reference

12 December 2020

Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis

1 reference

12 December 2020

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months

1 reference

12 December 2020

Ciprofloxacin is not a component of first-line TB

1 reference

12 December 2020

Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis

1 reference

12 December 2020

Treatment of multidrug-resistant tuberculosis in Taiwan

1 reference

12 December 2020

Fluoroquinolones: a new treatment for tuberculosis?

1 reference

12 December 2020

[Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis].

1 reference

12 December 2020

[Lomefloxacin in phthisiatric practice].

1 reference

12 December 2020

10.1002/14651858.CD004795.PUB4

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2743596

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2743596

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744519%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

23744519

2 references

Consolidated OpenCitations Corpus – April 2017

2743596